PN-881
Psoriasis, PsA, Hidradenitis Suppurativa, Spondyloarthritis
Phase 1Initiated Q4 '25
Key Facts
Indication
Psoriasis, PsA, Hidradenitis Suppurativa, Spondyloarthritis
Phase
Phase 1
Status
Initiated Q4 '25
Company
About Protagonist Therapeutics
Protagonist Therapeutics is a leader in peptide-based drug discovery, leveraging its proprietary Vectrix™ platform to overcome historical challenges of oral bioavailability and stability. The company has achieved significant milestones, including the FDA approval of icotrokinra for psoriasis and a pending NDA for rusfertide in polycythemia vera. Its strategy combines internal development of wholly-owned assets with strategic partnerships, like the one with Janssen for icotrokinra, to build a diversified, multi-indication portfolio.
View full company profile